WHO makes cancer recommendations
The World Health Organization (WHO) has explained its priorities to help save seven million people from cancer-related deaths. The WHO … read more »
ICR study points to delays in patient access
The Institute of Cancer Research (ICR) has published an analysis into the time taken from the launch of a product … read more »
EFPIA highlights ‘Time to Patient Access’ campaign
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has highlighted its ongoing project on the impact of access inequalities … read more »
Health Canada reports success of collaboration with USA and Australia
Health Canada has released results from its collaboration known as Project Orbis, linking international agencies to speed-up patient access. In … read more »
Case made for regulatory innovation in cancer research
The Institute of Cancer Research (ICR) has made the case that current regulation can sometimes prevent patient access to innovative … read more »
£8 million funding to improve cancer waiting times in Scotland
The Scottish Government has announced a further £8 million funding for cancer staff and services, with £4.8 million to be … read more »
Welsh Government announces new cancer waiting times metric
The Welsh Government has announced a new metric for measuring waiting-times for cancer services which will measure outcomes against a … read more »
Medicare coverage for CAR-T cell therapies announced
CMS has announced US nationwide coverage for CAR-T cell therapies, and has dropped its proposal of continued evidence-gathering by healthcare … read more »
AIFA announces funding of CAR-T cell therapy using new reimbursement approach
The Italian Medicines Agency (AIFA) has announced that it will be reimbursing CAR-T cell therapy Kymriah, using a new reimbursement … read more »
Tumour-agnostic drug receives positive opinion for conditional approval in EU-first
The EU looks set to authorise its first tumour-agnostic new cancer drug, already approved in the USA, Canada and Brazil. … read more »
